Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on April 16, 2025, covering events occurring on April 10, 2025. The filing addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statement data.
Material Changes
The primary material change reported is the departure of a director:
- Director Departure: Bertrand Loy informed the Company on April 10, 2025, that he will not stand for re-election at the 2025 Annual Meeting.
- Reason: The decision was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Current Roles: Mr. Loy has served on the Board since 2014 and currently acts as Lead Independent Director and a member of the Audit and Nominating and Governance Committees.
- Transition: He will continue to serve in his current roles until the conclusion of the 2025 Annual Meeting.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to the director's departure were disclosed beyond the standard statement that the departure was not due to disagreement.
Key Facts for Investor Verification
- Verify the date and agenda of the 2025 Annual Meeting to confirm the finalization of Mr. Loy's departure.
- Monitor subsequent filings for the election of a replacement director to fill the vacancy on the Board.
- Confirm that no other undisclosed disagreements exist between Mr. Loy and the Company, as stated in the filing.